A study to investigate the association between the acute response and long-term clinical response to galantamine in patients with mild to moderate Alzheimer’s Disease
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseNervous System Diseases
- Registration Number
- ISRCTN82825745
- Lead Sponsor
- Centre for Human Drug Research
- Brief Summary
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/34964149/ (added 31/10/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Clinical diagnosis of AD
2. Mini Mental State Examination (MMSE) score ranging from 18 to 26
3. Clinical Dementia Rating (CDR) score between 0.5 and 2.0
Exclusion Criteria
1. Previous or current use of CEIs, anticholinergic drugs or neuroleptics
2. Contraindications for the use of CEIs
3. Use of benzodiazepines 48 hours prior to the study days
4. History of psychiatric disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method